

Optimising TCT Outcomes

CMV Practice Survey & Statement

A/Prof Andrea S Henden, BSc, MBBS (Hons), FRACP, FRCPA, PhD, GAICD

Department of Haematology and Bone Marrow Transplantation, Cancer Care Services, Royal Brisbane and Women's Hospital, andrea.henden@health.qld.gov.au

Translational Cancer Immunotherapy Laboratory, QIMR Berghofer andrea.henden@qimrberghofer.edu.au

Faculty of Health, Medicine and Behavioural Science, University of Queensland a.henden@uq.edu.au

CMV

*The need for a current
practice statement*

- Most frequent and significant viral infection affecting transplant recipients
- New Therapeutics in prophylaxis and treatment
- Scope of impact in recipients of Chimeric Antigen Receptor T cell therapy unknown

ARTICLE



New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Party of EBMT

Simone Cesaro ¹✉, Per Ljungman ², Gloria Tridello¹, Malgorzata Mikulska ³, Lotus Wendel⁴, Jan Styczynski ⁵, Dina Averbuch ⁶ and Rafael de la Camara ⁷

ANZTCT Cytomegalovirus (CMV) practice survey for allogeneic haematopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

- Andrea Henden, Lynette Chee, Julia Clark, Rachel Conyers, Julian Cooney, David Gottlieb, Tim Prestidge, Richard Doocey, Madeleine Powys, Philip Selby, Gaurav Sutrave, Eric Wong, Nada Hamad
- Survey of 21 sites including 11 who deliver CAR T cell therapy
Over period of practice in 2024
- 26 cases of CMV disease in allogeneic recipients, 4 post CAR T

Article scope

- CMV protocols for monitoring, PeT and treatment
- Therapeutic choices
- Burden of disease
- Approach to R/R disease
- Role of Immunotherapy
- International guidelines contextualized to ANZ practice
- Evidence base for new therapies and role in ANZ

Acknowledgements

- Co-authors and survey respondents
- Sally Costello, WriteSource Medical